Funding for this research was provided by:
Francis Family Foundation (Parker B Francis Fellowship)
Canadian Health Services Research Foundation (Project Grant)
Article History
Received: 13 April 2021
Accepted: 17 August 2021
First Online: 31 August 2021
Declarations
:
: These studies were approved by the University of Calgary Animal Care and Use Committee, in accordance with the Canadian Council of Animal Care, protocol AC15-0061 and AC16-0204. No client-owned animals were used.
: Not applicable.
: N.G.J., A.R. and R.J.A.W declare the following competing interests. U.S. Patent Application No. 62/534,638, Status: provisional patent; “Method to Abate Acute Airway Hypersensitivity and Asthma Attacks.” Purpose: for the use of TRPV1 and LPAr blockade as a treatment for respiratory distress associated with acute asthmatic attack. Authors are also founders and/or shareholders of AazeinTx Inc., a clinical-stage University spinoff company investigating the use of a TRPV1 antagonist in asthma.